Status of programmed death-ligand 1 expression in sarcomas
Abstract Background Sarcomas are challenging to study because of their rarity and histomorphological complexity. PD1 and PD-L1 inhibitors showed a promising anti-tumor effect in solid tumors, where a relationship between PD-L1 expression and the objective response has been evidenced. Methods In this...
Main Authors: | Hyung Kyu Park, Mingi Kim, Minjung Sung, Seung Eun Lee, Yu Jin Kim, Yoon-La Choi |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-11-01
|
Series: | Journal of Translational Medicine |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s12967-018-1658-5 |
Similar Items
-
Programmed cell death protein-1 (PD-1) protects liver damage by suppressing IFN-γ expression in T cells in infants and neonatal mice
by: Xuangjie Guo, et al.
Published: (2021-07-01) -
Programmed Death Ligand 1 Indicates Pre-Existing Adaptive Immune Response by Tumor-Infiltrating CD8<sup>+</sup> T Cells in Non-Small Cell Lung Cancer
by: Yi-Ming Li, et al.
Published: (2019-10-01) -
Clinical outcome of osteosarcoma and its correlation with programmed death-ligand 1 and T cell activation markers
by: Yoshida K, et al.
Published: (2019-04-01) -
Atorvastatin Attenuates Programmed Death Ligand-1 (PD-L1) Induction in Human Hepatocellular Carcinoma Cells
by: Thuzar Hla Shwe, et al.
Published: (2021-08-01) -
Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8+ T-cell immune responses
by: Zhu Y, et al.
Published: (2018-10-01)